Nise H Yamaguchi1, Ingrid A Mayer2, Artur Malzyner3, Carlos Jc de Andrade4, Andre M Murad5, Auro Del Giglio6, Venancio Alves7. 1. University of São Paulo Medical School and Institute of Advances in Medicine, São Paulo, Brazil ; 2. Vanderbilt-Ingram Cancer Center, Nashville, TN, USA ; 3. Hospital Israelita Albert Einstein and Heliopolis Hospital and Clínica de Oncologia Médica, São Paulo, Brazil ; 4. National Cancer Institute, Rio de Janeiro, Brazil ; 5. Oncology Department, Hospital das Clinicas, Federal University of Minas Gerais, Belo Horizonte, Brazil ; 6. ABC Foundation Medical School, ABC São Paulo, Brazil ; 7. University of São Paulo School of Medicine, São Paulo, Brazil.
Abstract
BACKGROUND: This pilot, open-label study examined the safety and tolerability (primary objective) and efficacy (secondary objective) of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with advanced or refractory gastrointestinal (GI) tumors of epithelial origin. METHODS: Patients were administered gefitinib (250 mg/day) plus celecoxib (400 mg twice daily). In the event of toxicity, dose interruptions were permitted and a single celecoxib dose reduction was allowed. RESULTS: Thirty patients (median age 60 years) with primary colorectal (25 patients), pancreatic (3 patients), esophageal (1 patient), or gall bladder (1 patient) tumors were recruited, 29 of whom had received prior chemotherapy. Adverse events (AEs) were generally mild and consisted mainly of acne, diarrhea, and nausea. Few severe AEs were noted. There were no withdrawals or deaths due to AEs. Dose reductions for celecoxib were reported for five patients, in three cases due to toxicity. Stable disease was confirmed in 12 patients (40%), with progressive disease in 18 patients (60%). CONCLUSIONS: After study completion, safety issues relating to the long-term use of COX-2 inhibitors have been raised. However, in this pilot study, the combination of gefitinib and celecoxib was generally well tolerated in patients with advanced GI cancer.
BACKGROUND: This pilot, open-label study examined the safety and tolerability (primary objective) and efficacy (secondary objective) of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with advanced or refractory gastrointestinal (GI) tumors of epithelial origin. METHODS:Patients were administered gefitinib (250 mg/day) plus celecoxib (400 mg twice daily). In the event of toxicity, dose interruptions were permitted and a single celecoxib dose reduction was allowed. RESULTS: Thirty patients (median age 60 years) with primary colorectal (25 patients), pancreatic (3 patients), esophageal (1 patient), or gall bladder (1 patient) tumors were recruited, 29 of whom had received prior chemotherapy. Adverse events (AEs) were generally mild and consisted mainly of acne, diarrhea, and nausea. Few severe AEs were noted. There were no withdrawals or deaths due to AEs. Dose reductions for celecoxib were reported for five patients, in three cases due to toxicity. Stable disease was confirmed in 12 patients (40%), with progressive disease in 18 patients (60%). CONCLUSIONS: After study completion, safety issues relating to the long-term use of COX-2 inhibitors have been raised. However, in this pilot study, the combination of gefitinib and celecoxib was generally well tolerated in patients with advanced GI cancer.
Entities:
Keywords:
Gefitnib; celecoxib; gastrointestinal cancer (GI cancer)
Authors: Mace L Rothenberg; Bonnie LaFleur; Donna E Levy; Mary Kay Washington; Sherry L Morgan-Meadows; Ramesh K Ramanathan; Jordan D Berlin; Al B Benson; Robert J Coffey Journal: J Clin Oncol Date: 2005-12-20 Impact factor: 44.544
Authors: Malcolm Ranson; Lisa A Hammond; David Ferry; Mark Kris; Andrew Tullo; Philip I Murray; Vince Miller; Steve Averbuch; Judy Ochs; Charles Morris; Andrea Feyereislova; Helen Swaisland; Eric K Rowinsky Journal: J Clin Oncol Date: 2002-05-01 Impact factor: 44.544
Authors: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay Journal: JAMA Date: 2003-10-22 Impact factor: 56.272
Authors: F Cappuzzo; G Finocchiaro; E Rossi; P A Jänne; C Carnaghi; C Calandri; K Bencardino; C Ligorio; F Ciardiello; T Pressiani; A Destro; M Roncalli; L Crino; W A Franklin; A Santoro; M Varella-Garcia Journal: Ann Oncol Date: 2007-10-31 Impact factor: 32.976
Authors: David R Ferry; Mark Anderson; Kate Beddard; Simon Tomlinson; Paul Atherfold; Jolanta Obszynska; Rebecca Harrison; Janusz Jankowski Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Zeenat Mirza; Hans-Juergen Schulten; Hasan Ma Farsi; Jaudah A Al-Maghrabi; Mamdooh A Gari; Adeel Ga Chaudhary; Adel M Abuzenadah; Mohammed H Al-Qahtani; Sajjad Karim Journal: PLoS One Date: 2015-03-19 Impact factor: 3.240